Sluyser M
Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam.
Clin Biochem. 1992 Dec;25(6):407-14. doi: 10.1016/0009-9120(92)90015-k.
Recent evidence suggests that the progression to hormone resistance in some breast tumors is due to mutations in the estrogen receptor (ER). Various types of ER variants have been found in breast cancer biopsies and breast cancer cell lines. The ER variants include dominant-positive receptors that are transcriptionally active in the absence of estrogen, and dominant-negative receptors that are themselves transcriptionally inactive but prevent the action of the normal receptor. The mechanisms by which these variants cause loss of hormonal control is becoming clear. ER variants may be prognostic factors for breast cancer. By modifying the action of ER variants, it should be possible to develop new strategies for treatment of malignant breast disease.
最近的证据表明，某些乳腺肿瘤对激素产生耐药性的进展是由于雌激素受体（ER）发生了突变。在乳腺癌活检组织和乳腺癌细胞系中发现了各种类型的ER变体。ER变体包括在无雌激素情况下具有转录活性的显性阳性受体，以及自身无转录活性但能阻止正常受体发挥作用的显性阴性受体。这些变体导致激素控制丧失的机制正逐渐明晰。ER变体可能是乳腺癌的预后因素。通过改变ER变体的作用，应该有可能开发出治疗恶性乳腺疾病的新策略。
